Lista de obras - Roseline d'Oiron - Dominio Público Uruguay

A Laboratory Phenotype/Genotype Correlation of 1167 French Patients From 670 Families With von Willebrand Disease: A New Epidemiologic Picture

artículo científico publicado en 2016

A systematic approach to controlling problem bleeds in patients with severe congenital haemophilia A and high-titre inhibitors.

artículo científico publicado en 2007

Achievements, challenges and unmet needs for haemophilia patients with inhibitors: Report from a symposium in Paris, France on 20 November 2014.

artículo científico publicado en 2016

Acquired haemophilia A associated with HIV infection: a rare disease.

artículo científico publicado en 2014

Analyses of the FranceCoag cohort support immunogenicity differences among one plasma-derived and two recombinant factor VIII brands in boys with severe hemophilia A.

artículo científico publicado en 2017

Characterization of four novel molecular changes in the promoter region of the factor VIII gene

artículo científico publicado en 2013

Clinical management of woman with bleeding disorders: A survey among European haemophilia treatment centres

scientific article published on 27 May 2020

Common themes and challenges in hemophilia care: a multinational perspective

artículo científico publicado en 2018

Deletion of alanine 2201 in the FVIII C2 domain results in mild hemophilia A by impairing FVIII binding to VWF and phospholipids and destroys a major FVIII antigenic determinant involved in inhibitor development.

artículo científico publicado en 2003

Detection of 95 novel mutations in coagulation factor VIII gene F8 responsible for hemophilia A: results from a single institution.

artículo científico publicado en 2006

Development of inhibitory antibodies to therapeutic factor VIII in severe hemophilia A is associated with microsatellite polymorphisms in the HMOX1 promoter.

scientific article published on 28 May 2013

Erythrocyte indices and iron stores in cord blood

artículo científico publicado en 1995

Evaluation of algorithms for the treatment of problem bleeding episodes in patients with hemophilia having inhibitors

artículo científico publicado en 2014

Experiences with continuous infusion of recombinant activated factor VII.

artículo científico publicado en 1998

Factor VIII bypasses CD91/LRP for endocytosis by dendritic cells leading to T-cell activation.

artículo científico publicado en 2008

Factor VIII genotype and inhibitor development in patients with haemophilia A: highest risk in patients with splice site mutations.

artículo científico publicado en 2008

Factor XI deficiency: identification of six novel missense mutations (P23L, P69T, C92G, E243D, W497C and E547K)

scientific article published on 01 August 2005

First identification and expression of a type 2N von Willebrand disease mutation (E1078K) located in exon 25 of von Willebrand factor gene

article

Functional mapping of anti-factor IX inhibitors developed in patients with severe hemophilia B.

artículo científico publicado en 2001

Hepatitis A in French hemophiliacs.

artículo científico publicado en 1994

How I treat inhibitors in haemophilia.

artículo científico publicado en 2012

Impact of choice of treatment for bleeding episodes on inhibitor outcome in patients with mild/moderate hemophilia a and inhibitors.

artículo científico publicado en 2006

Independent adjudicator assessments of platelet refractoriness and rFVIIa efficacy in bleeding episodes and surgeries from the multinational Glanzmann's thrombasthenia registry.

artículo científico publicado en 2017

Kikuchi's histiocytic necrotizing lymphadenitis of toxoplasmic origin may be due to a local reactional mechanism in lymph nodes.

artículo científico publicado en 1995

Malignant disease in the haemophilic population: moving towards a management consensus?

artículo científico publicado en 2012

Managing women-specific bleeding in inherited bleeding disorders: A multidisciplinary approach

artículo científico publicado en 2020

Metabolic, hepatic and muscular changes during zidovudine therapy: a drug-induced mitochondrial disease?

artículo científico publicado en 1994

Mild/moderate haemophilia A: new insights into molecular mechanisms and inhibitor development.

scientific article published on July 2008

Modeling costs and outcomes associated with a treatment algorithm for problem bleeding episodes in patients with severe hemophilia a and high-titer inhibitors

artículo científico publicado en 2011

Molecular analysis of the fibrinogen gene cluster in 16 patients with congenital afibrinogenemia: novel truncating mutations in the FGA and FGG genes

article

New Insights Into the Treatment of Glanzmann Thrombasthenia

artículo científico publicado en 2016

Partnering to change the world for people with haemophilia: 6(th) Haemophilia Global Summit, Prague, Czech Republic, 24-26(th) September 2015.

artículo científico publicado en 2016

Prophylactic and therapeutic recombinant factor VIIa administration to patients with Glanzmann's thrombasthenia: results of an international survey.

artículo científico publicado en 2004

Protein A Sepharose immunoadsorption can restore the efficacy of platelet concentrates in patients with Glanzmann's thrombasthenia and anti-glycoprotein IIb-IIIa antibodies

artículo científico publicado en 2002

Protein A sepharose immunoadsorption: immunological and haemostatic effects in two cases of acquired haemophilia.

artículo científico publicado en 2001

Recombinant activated factor VII (NovoSeven) treatment of platelet-related bleeding disorders. International Registry on Recombinant Factor VIIa and Congenital Platelet Disorders Group.

artículo científico publicado en 2000

Recombinant factor VIII products and inhibitor development in previously untreated boys with severe hemophilia A.

artículo científico publicado en 2014

Successful immune tolerance induction by FVIII in hemophilia A patients with inhibitor may occur without deletion of FVIII-specific T cells.

artículo científico publicado en 2011

The first Team Haemophilia Education meeting, 2015, Amsterdam, The Netherlands.

artículo científico publicado en 2016

The international, prospective Glanzmann Thrombasthenia Registry: treatment and outcomes in surgical intervention

artículo científico publicado en 2015

The international, prospective Glanzmann Thrombasthenia Registry: treatment modalities and outcomes of non-surgical bleeding episodes in patients with Glanzmann thrombasthenia

artículo científico

The second Team Haemophilia Education Meeting, 2016, Frankfurt, Germany

artículo científico publicado en 2017

Transmission of human parvovirus B19 by plasma derived factor VIII concentrates

scientific article published on 01 December 1994

Use of recombinant factor VIIa (NovoSeven) in patients with Glanzmann thrombasthenia.

artículo científico publicado en 2001

Women and girls with haemophilia: Lessons learned

artículo científico publicado en 2020

[Mild hemophilia A fortuitously discovered during Henoch-Schönlein purpura].

artículo científico publicado en 2015

[Which urologic treatment alternatives are there for the hemophiliac patient?]

artículo científico publicado en 2000

Lista de obras de Roseline d'Oiron

A Laboratory Phenotype/Genotype Correlation of 1167 French Patients From 670 Families With von Willebrand Disease: A New Epidemiologic Picture

A systematic approach to controlling problem bleeds in patients with severe congenital haemophilia A and high-titre inhibitors.

Achievements, challenges and unmet needs for haemophilia patients with inhibitors: Report from a symposium in Paris, France on 20 November 2014.

Acquired haemophilia A associated with HIV infection: a rare disease.

Analyses of the FranceCoag cohort support immunogenicity differences among one plasma-derived and two recombinant factor VIII brands in boys with severe hemophilia A.

Characterization of four novel molecular changes in the promoter region of the factor VIII gene

Clinical management of woman with bleeding disorders: A survey among European haemophilia treatment centres

Common themes and challenges in hemophilia care: a multinational perspective

Deletion of alanine 2201 in the FVIII C2 domain results in mild hemophilia A by impairing FVIII binding to VWF and phospholipids and destroys a major FVIII antigenic determinant involved in inhibitor development.

Detection of 95 novel mutations in coagulation factor VIII gene F8 responsible for hemophilia A: results from a single institution.

Development of inhibitory antibodies to therapeutic factor VIII in severe hemophilia A is associated with microsatellite polymorphisms in the HMOX1 promoter.

Erythrocyte indices and iron stores in cord blood

Evaluation of algorithms for the treatment of problem bleeding episodes in patients with hemophilia having inhibitors

Experiences with continuous infusion of recombinant activated factor VII.

Factor VIII bypasses CD91/LRP for endocytosis by dendritic cells leading to T-cell activation.

Factor VIII genotype and inhibitor development in patients with haemophilia A: highest risk in patients with splice site mutations.

Factor XI deficiency: identification of six novel missense mutations (P23L, P69T, C92G, E243D, W497C and E547K)

First identification and expression of a type 2N von Willebrand disease mutation (E1078K) located in exon 25 of von Willebrand factor gene

Functional mapping of anti-factor IX inhibitors developed in patients with severe hemophilia B.

Hepatitis A in French hemophiliacs.

How I treat inhibitors in haemophilia.

Impact of choice of treatment for bleeding episodes on inhibitor outcome in patients with mild/moderate hemophilia a and inhibitors.

Independent adjudicator assessments of platelet refractoriness and rFVIIa efficacy in bleeding episodes and surgeries from the multinational Glanzmann's thrombasthenia registry.

Kikuchi's histiocytic necrotizing lymphadenitis of toxoplasmic origin may be due to a local reactional mechanism in lymph nodes.

Malignant disease in the haemophilic population: moving towards a management consensus?

Managing women-specific bleeding in inherited bleeding disorders: A multidisciplinary approach

Metabolic, hepatic and muscular changes during zidovudine therapy: a drug-induced mitochondrial disease?

Mild/moderate haemophilia A: new insights into molecular mechanisms and inhibitor development.

Modeling costs and outcomes associated with a treatment algorithm for problem bleeding episodes in patients with severe hemophilia a and high-titer inhibitors

Molecular analysis of the fibrinogen gene cluster in 16 patients with congenital afibrinogenemia: novel truncating mutations in the FGA and FGG genes

New Insights Into the Treatment of Glanzmann Thrombasthenia

Partnering to change the world for people with haemophilia: 6(th) Haemophilia Global Summit, Prague, Czech Republic, 24-26(th) September 2015.

Prophylactic and therapeutic recombinant factor VIIa administration to patients with Glanzmann's thrombasthenia: results of an international survey.

Protein A Sepharose immunoadsorption can restore the efficacy of platelet concentrates in patients with Glanzmann's thrombasthenia and anti-glycoprotein IIb-IIIa antibodies

Protein A sepharose immunoadsorption: immunological and haemostatic effects in two cases of acquired haemophilia.

Recombinant activated factor VII (NovoSeven) treatment of platelet-related bleeding disorders. International Registry on Recombinant Factor VIIa and Congenital Platelet Disorders Group.

Recombinant factor VIII products and inhibitor development in previously untreated boys with severe hemophilia A.

Successful immune tolerance induction by FVIII in hemophilia A patients with inhibitor may occur without deletion of FVIII-specific T cells.

The first Team Haemophilia Education meeting, 2015, Amsterdam, The Netherlands.

The international, prospective Glanzmann Thrombasthenia Registry: treatment and outcomes in surgical intervention

The international, prospective Glanzmann Thrombasthenia Registry: treatment modalities and outcomes of non-surgical bleeding episodes in patients with Glanzmann thrombasthenia

The second Team Haemophilia Education Meeting, 2016, Frankfurt, Germany

Transmission of human parvovirus B19 by plasma derived factor VIII concentrates

Use of recombinant factor VIIa (NovoSeven) in patients with Glanzmann thrombasthenia.

Women and girls with haemophilia: Lessons learned

[Mild hemophilia A fortuitously discovered during Henoch-Schönlein purpura].

[Which urologic treatment alternatives are there for the hemophiliac patient?]